Sulfated Polypeptide Systemic Delivery Muscle Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering polypeptide agents, such as antibodies and replacement therapies, face challenges in targeting therapeutically relevant cells and tissues while minimizing toxicity, particularly in avoiding accumulation in non-target organs like the liver and kidneys.
Innovation Solution
The use of sulfated polypeptide agents for systemic intravenous delivery, which includes sulfation of polypeptides to enhance targeting to muscle tissues and reduce accumulation in liver and kidneys, achieved through the incorporation of sulfated residues and specific promoter nucleic acid sequences for expression in muscle cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If non-sulfated polypeptide agents are used for systemic delivery, then the delivery process is simpler, but delivery to target tissues (muscle) is insufficient and accumulation in non-target organs (liver, kidney) occurs
Solution Approach 1:
The patent applies chemical modification by introducing sulfated residues into the polypeptide agent, fundamentally changing its biochemical properties. This parameter change enables selective interaction with muscle tissues through sulfate group recognition mechanisms, thereby improving delivery to target tissues while reducing accumulation in non-target organs like liver and kidney.
Solution Approach 2:
The sulfation modification creates localized regions of high affinity for muscle tissues. The sulfated residues provide specific binding characteristics that are concentrated in certain regions of the polypeptide structure, enabling preferential targeting to muscle while maintaining overall system simplicity.
2Reliability
If sulfated polypeptide agents are used for systemic delivery, then delivery to target tissues is improved and toxicity is reduced, but the complexity of the polypeptide structure increases
Solution Approach 1:
The patent modifies existing polypeptide structures by introducing sulfated residues at specific positions, rather than creating entirely new complex structures. This parameter-based modification approach maintains the overall simplicity of the polypeptide while achieving the desired therapeutic effects through controlled chemical changes.
3Reliability
If higher dosages of polypeptide agents are used, then therapeutic efficacy increases, but toxicity and required dosing frequency increase
Solution Approach 1:
By changing the biochemical parameters of the polypeptide through sulfation, the patent enhances the agent's affinity for target tissues. This parameter change allows for more efficient delivery and reduced dosage requirements, as the sulfated polypeptide achieves better therapeutic efficacy at lower concentrations compared to non-sulfated forms.
Data Source
AI summary
The present disclosure includes, among other things, methods and compositions for systemic (e.g., intravenous) delivery of sulfated polypeptide agents. In various embodiments, the present disclosure includes methods and compositions that reduce toxicity of systemic administration of polypeptide agents. In various embodiments, the present disclosure includes methods and compositions that cause or increase delivery of polypeptide agents to target cells, tissues, or organs (e.g., muscle, e.g., skeletal muscle, cardiac muscle, and/or diaphragm) following systemic (e.g., intravenous) delivery. In various embodiments, the present disclosure provides promoter sequences that achieve advantageous expression of operably linked coding sequences in muscle, e.g., in skeletal muscle, cardiac muscle, and/or diaphragm.